About EyeTech
EyeTech is a Healthcare company based in Hanover (United States) founded in 1996, and was acquired by OSI Pharmaceuticals in August 2005. Biopharmaceuticals for treatment of Age related Macular degeneration. EyeTech has raised $133.5 million across 3 funding rounds from investors including J P Morgan, Merrill Lynch and BB Biotech. Its focus areas include Life Sciences, Ophthalmology, Drugs and Diversified. Its competitors include Kriya Therapeutics, Annexon and Aldeyra; 3 of its 3 listed competitors have raised funding.
Company details
Founded in 1996, EyeTech operates in the biotechnology sector, focusing on retinal disease treatments. Products such as Macugen, a pegaptanib sodium injection and anti-VEGF inhibitor, are provided for neovascular age-related macular degeneration. Access programs are also offered to assist patients with reimbursement. The company is based in Hanover, United States, and maintains a domain at eyetech.com.
- Headquarters Hanover, United States
- Stage Acquired
- SectorsHealthcare
- Website eyetech.com
- Acquired by OSI Pharmaceuticals (Aug 2005)
- Total Equity Funding$133.5M (USD)
in 3 rounds
- Latest Funding Round$10M (USD), Post-IPO
Feb 2004
- InvestorsJ P Morgan
& 6 more
- Acquired byOSI Pharmaceuticals
(Aug 2005)
Funding Insights of EyeTech
EyeTech has successfully raised a total of $133.5M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $10 million completed in February 2004. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $133.5M
- Total Rounds 3
- Last Round Post-IPO — $10M
- First Round $108.5M
(Aug 2001)
- Investors Count 6
All 3 funding rounds of EyeTech with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2004 | $10M | Post-IPO | – | – | – |
| Feb 2003 | $25M | Series D | – | – | – |
| Aug 2001 | $108.5M | Series C | – | – |
7 investors in total: 7 institutional.
Investors in EyeTech
EyeTech has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include J P Morgan, Merrill Lynch and BB Biotech.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on healthcare companies | altapartners.com | Jackson, United States | ||
PE firm investing in Asia and Europe | 1993 | bbbiotech.ch | Schaffhausen, Switzerland | |
Venture capital fund focused on early-stage healthcare startups | svhealthinvestors.com | Boston, United States | ||
Invests in biotech firms developing life-saving drugs and technologies. | mpmcapital.com | |||
Commercial bank | 1990 | ml.com | New York, United States | |
Comprehensive financial services are provided to corporations and individuals. | 1799 | jpmorgan.com | New York, United States | |
Gene-targeted small molecule drugs for cancer and diabetes are developed. | 1983 | osip.com | Melville, United States |
Investor details for EyeTech
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of EyeTech
5 dated milestones of EyeTech across 9 years, from founding to its latest funding, stage changes and deals.
- Founded EyeTech is founded.
- Funding First funding round of $108.5M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $10.0M.
- Exit Acquired by OSI Pharmaceuticals.
Competitors of EyeTech
EyeTech has 3 listed competitors in our database, 3 of them funded. They include Kriya Therapeutics, Annexon and Aldeyra.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| annexonbio.com | 2011 | San Francisco, United States | $256M | 80 | Developer of antibodies to treat complement-mediated neurodegenerative diseases | |
| aldeyra.com | 2004 | Lexington, United States | $4.79M | 30 | Drug candidates for immune-mediated diseases are developed by Aldeyra. |
Detailed competitors of EyeTech
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Ophthalmology
3 companies that operate in the same segment as EyeTech (Ophthalmology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of a wide range of eye care products | 1945 | Fort Worth, Texas, United States | USD 171.61 M | USD 9.64 B | 25,600 | |
Genetic medicines are developed by 4DMT for transformative therapies. | 2013 | Emeryville, California, United States | USD 186.59 M | USD 85.21 M | 227 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about EyeTech
EyeTech was founded in 1996 and raised its 1st funding round 5 years after it was founded.
EyeTech is headquartered in Hanover, United States. It is registered at Hanover, New Hampshire, United States.
EyeTech is a funded company, having raised a total of $133.5M across 3 funding rounds to date. The company's 1st funding round was a Series C of $108.5M, raised on Aug 2001.
Founded in 1996, EyeTech operates in the biotechnology sector, focusing on retinal disease treatments. Products such as Macugen, a pegaptanib sodium injection and anti-VEGF inhibitor, are provided for neovascular age-related macular degeneration. Access programs are also offered to assist patients with reimbursement. The company is based in Hanover, United States, and maintains a domain at eyetech.com.
EyeTech's top competitors include Annexon, Aldeyra and Kriya Therapeutics.
EyeTech has 7 investors. Key investors include J P Morgan, Merrill Lynch, BB Biotech, OSI Pharmaceuticals, and Turmeric Acquisition Corp.
Yes. EyeTech was acquired by OSI Pharmaceuticals in August 2005.